Youcare Pharmaceutical (SH:688658) Ge Long Hui A P P·2025-11-05 08:37Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) has received approval from the National Medical Products Administration for its subsidiary Yuyuan Kechuang and Hangzhou Tianlong to conduct Phase I clinical trials for YKYY013 injection, aimed at treating chronic hepatitis B virus infection [1] Company Summary - YKYY013 injection is a chemically synthesized double-stranded siRNA drug developed by Yuyuan Kechuang and Hangzhou Tianlong, utilizing an N-acetylgalactosamine (GalNAc) ligand [1] - The drug works through RNA interference to effectively silence the HBV genome's messenger RNA (mRNA), thereby inhibiting the production of hepatitis B pathogen proteins and suppressing HBV replication [1] - The ultimate goal of YKYY013 is to create conditions for host immune reconstitution, leading to the functional cure of hepatitis B [1] Industry Summary - The approval for clinical trials indicates a significant advancement in the treatment options available for chronic hepatitis B virus infections, which remains a major public health concern globally [1]